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Abstract
Background: Human African trypanosomiasis is fatal without treatment. The long post-treatment follow-up (24 months)
required to assess cure complicates patient management and is a major obstacle in the development of new therapies. We
analyzed individual patient data from 12 programs conducted by Me´decins Sans Frontie`res in Uganda, Sudan, Angola,
Central African Republic, Republic of Congo and Democratic Republic of Congo searching for early efficacy indicators.
Methodology/Principal Findings: Patients analyzed had confirmed second-stage disease with complete follow-up and
confirmed outcome (cure or relapse), and had CSF leucocytes counts (CSFLC) performed at 6 months post-treatment. We
excluded patients with uncertain efficacy outcome: incomplete follow-up, death, relapse diagnosed with CSFLC below 50/
mL and no trypanosomes. We analyzed the 6-month CSFLC via receiver-operator-characteristic curves. For each cut-off value
we calculated sensitivity, specificity and likelihood ratios (LR+ and LR2). We assessed the association of the optimal cut-off
with the probability of relapsing via random-intercept logistic regression. We also explored two-step (6 and 12 months)
composite algorithms using the CSFLC.
The most accurate cut-off to predict outcome was 10 leucocytes/mL (n = 1822, 76.2% sensitivity, 80.4% specificity, 3.89
LR+, 0.29 LR2). Multivariate analysis confirmed its association with outcome (odds ratio = 17.2). The best algorithm
established cure at 6 months with ,= 5 leucocytes/mL and relapse with .= 50 leucocytes/mL; patients between these
values were discriminated at 12 months by a 20 leucocytes/mL cut-off (n = 2190, 87.4% sensitivity, 97.7% specificity, 37.84
LR+, 0.13 LR2).
Conclusions/Significance: The 6-month CSFLC can predict outcome with some limitations. Two-step algorithms enhance
the accuracy but impose 12-month follow-up for some patients. For early estimation of efficacy in clinical trials and for
individual patients in the field, several options exist that can be used according to priorities.
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Introduction
Human African trypanosomiasis (HAT) or sleeping sickness,
caused by Trypanosoma brucei gambiense (most common form, West
and Central Africa) and rhodesiense (East and Southern Africa), is
fatal unless treated. After infection, the disease progresses from the
easily treatable haemolymphatic first stage to the meningoenceph-
alitic second stage, when parasites invade the central nervous
system.
Patients who receive treatment can not be considered cured
immediately, because the parasite may remain viable, redevelop-
ing fully the disease many months later. A long post-treatment
follow-up period is thus required to assess cure [1]. This follow-up
time is fixed at 24 months by convention, although in comparative
clinical trials it is considered acceptable to measure the efficacy at
18 months [2]. Follow-up consists of control visits generally every 6
months when lymph, blood and cerebrospinal fluid (CSF) are
examined. The detection of trypanosomes in any body fluid
unequivocally identifies a relapse. Unfortunately, parasites are
often not detected early enough to allow for timely re-treatment,
plus many patients do not adhere to this demanding and invasive
follow-up schedule. To better detect the relapses and avert the risk
for serious sequelae or death, the variation in number of white
blood cells (WBC) in CSF is widely used as a proxy marker of
relapse. Other markers of relapse are under investigation and not
in routine field use.
Because most HAT patients are located in remote rural areas,
the post-therapeutic follow-up is particularly challenging: poverty,
distance, bad roads, lack of transportation, subsistence priorities,
displacement (sometimes conflict related), add to the fear of the
lumbar puncture. As a result, patients’ compliance with follow-up
decreases markedly after the first assessment at 6 months [3].
Such long follow-up is a handicap not only for routine patient
management but also for therapeutic efficacy studies [4], and
particularly when a sequence of clinical studies is required (e.g.
dose-finding studies). Some time can be saved when a given
investigational treatment is assumed to have insufficient efficacy
due to early failures surpassing a pre-defined threshold. However,
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when the cumulative failure rate is below that threshold, the risk of
subsequent final outcome (cure or relapse) can not be predicted.
Research on ways of shortening the follow-up is scarce. One
study suggests that HAT patients with ,5 CSF leucocytes/mL at 6
months are at low risk of relapse (negative predictive value .0.93,
n = 146) [5] and that at 6 and 12 months, patients with $50 and
$20CSF leucocytes/mL, respectively, are at high risk. Another
study tested an algorithm combining 6 and 12 months CSF exams
on a cohort of 206 treated patients showing 97.8% specificity and
94.4% sensitivity to predict relapse [6]. Considering that these
promising findings originated from relatively small cohorts,
recruited each time in one single centre (Bwamanda and Mbuji
Mayi, DRC, respectively), and that confirmed and unconfirmed
efficacy outcomes (lost to follow-up, deaths during follow-up, etc)
were mixed in the assessment via assumptions, further research is
needed on larger datasets and with more restrictive selection
criteria.
To meet this goal, we consolidated individual-patient data from
12 sites in Uganda, Sudan, Angola, Central African Republic,
Republic of Congo and Democratic Republic of Congo where
Me´decins Sans Frontie`res (MSF) had conducted HAT programs,
and we selected patients with confirmed diagnosis, confirmed
stage, complete follow-up (thus confirmed outcome), and meeting
a restrictive, laboratory-confirmed definition of relapse, so as to
maximize information certainty. Our analysis aimed at identifying
early efficacy indicators using the CSF leucocytes count at 6 and
12 months after treatment.
Methods
Ethics statement
The study received ethical clearance from the Me´decins Sans
Frontie`res International Ethical Review Board (Geneva, Switzer-
land). All data analyzed were anonymized from the start.
Using a large pooled dataset from routine MSF gambiense HAT
control programs, we selected patients with confirmed second-
stage disease and having received second-stage treatment, who
completed their follow-up (minimum 22 months) until confirma-
tion of an outcome (cured or relapsed) and who had a CSF
leucocytes count performed at 6 months post-treatment. We
considered 22 months as complete follow-up because in practice
patients coming for control at 22–23 months are not asked to
come again at 24 months.
Second stage was defined by the finding of trypanosomes in
blood, lymph nodes or CSF, with $20 leucocytes/mL in CSF.
We excluded patients who (i) had missing or incoherent data on
key variables, or (ii) died during treatment or follow-up, or (iii) were
diagnosed with relapse before 6 months or later than 36 months post
treatment, or (iv) for the first analysis only: relapsed at 6 months.
Individuals who relapsed before 6 months were excluded
because they do not contribute to the objectives of this analysis,
and those relapsing after 36 months because they are less certainly
distinguishable from reinfections.
Cure was defined as absence of trypanosomes in all body fluids
and ,= 20 leucocytes in CSF at $22 months post-treatment; and
relapse as trypanosomes detected in any body fluid or $50 CSF
leucocytes/mL anytime [7]. Patients diagnosed with relapse
without meeting this definition were excluded. We kept the
patients who continued on follow-up despite having $50 CSF
leucocytes/mL and who had a confirmed outcome later (either
cure or relapse).
The strict inclusion criteria aimed at strengthening the validity
of the results by focusing on patients that provide unequivocal
information, using the advantage of having a large cohort.
We defined tolerance windows for each planned follow-up visit:
6 (5–9); 12 (10–16); 18 (17–21); and 24 ($22) months [2].
Melarsoprol treatment included the following regimens: one
series of 10 daily injections; 2 or 3 series of 3 injections; and 3
series of 4 injections. Eflornithine included series of either 7 or 14
days, all at 400 mg/kg/day divided in 4 infusions per day.
Combination treatment included melarsoprol-eflornithine, nifurti-
mox-eflornithine and melarsoprol-nifurtimox co-administrations.
Statistical analysis
We used the Wilcoxon test to compare CSF leucocytes between
different groups of patients. We plotted the evolution of CSF
leucocytes (median, IQR) during the follow-up, overall and by
treatment received.
First analysis. We analyzed the relative change (as a percent
reduction) of the CSF leucocytes between baseline (pre-treatment)
and 6-months, per patient. We also analyzed the absolute count at
6 months independently of the baseline count. We assessed the
accuracy of these 2 diagnostic tests to predict relapse using the
receiver-operator-characteristic (ROC) curve and we reported the
area under the curve (AUC) with its 95% confidence interval (CI)
for each test. For each cut-off of the marker, sensitivity, specificity,
positive likelihood ratio (LR+) and negative likelihood ratio (LR2)
were reported with their respective 95% CI [8–9].
A random-intercept logistic regression was fitted to analyze the
effect of the chosen cut-off taking into account several baseline
individual characteristics. The threshold p-value to include factors
in the initial model was 0.4.
Second analysis. following the composite algorithm in two
steps at 6 and 12 months proposed by Mumba et al. (at 6 months
patients with ,= 5 leucocytes/mL are considered cured and with
.= 50 leucocytes/mL are considered relapsed, and at 12 months
all remaining patients are discriminated with a cut-off at 20
leucocytes/mL) [6], we explored various combinations of cut-off
values. The notation we used for the algorithms features the three
cut-off values of CSF leukocytes as follows: (i) lower cut-off at 6
months (cure); (ii) upper cut-off at 6 months (relapse), and (iii)
unique cut-off at 12 months.
Author Summary
Because Human African trypanosomiasis is fatal, it is crucial
for the patient to determine if curative treatment has been
effective. Unfortunately this is not possible without a 24-
month laboratory follow-up, which is problematic and
largely unaccomplished in the field reality. Studies that
assessed early indicators have used small cohorts, yielding
limited statistical power plus potential bias because of
including patients with equivocal outcome. We tackled
this problem by pooling a large dataset which allowed for
selecting cases providing strictly unequivocal information,
still numerous enough to produce sound statistical
evidence. We studied predictors based on the CSF
leucocytes count, a laboratory technique already available
in the field, evaluating their predictive power at 6 and 12
months post-treatment. We found a predictor at 6 months
(10 leucocytes/mL of CSF) that has sub-optimal accuracy
but may be valuable in some particular situations, plus
two-step algorithms at 6 and 12 months that offer
sufficient confidence to shorten the patients’ follow-up.
Until better biomarkers are identified, these findings
represent a significant advance for this neglected disease.
Benefits are foreseen both for patients and for overbur-
dened treatment facilities. In addition, research for new
treatments can be accelerated by using early predictors.
Early Efficacy Prediction for HAT
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Stata 10 software (StataCorp, College Station, Texas, USA) was
used to perform all the data analysis.
Results
Patients selected were 1822 for the first analysis and 2190 for
the second analysis (Figure 1) and had been diagnosed between
September 1995 and February 2006. Throughout this time period
the same diagnostic tools were used. The largest portion of the
cohort was from the centers of Omugo, Northern Uganda (44%)
and Ibba, Southern Sudan (21%), as these two sites achieved
higher follow-up compliance by investing specific resources.
Baseline characteristics are shown in Table 1.
Post-therapeutic evolution of the CSF leucocytes count
At pre-treatment, the CSF leucocytes count was not different
between the 1460 patients who cured (median 137.5 cells, IQR
Figure 1. Study profile: selection of study patients. Patients from 12 Me´decins Sans Frontie`res sites in Uganda, Sudan, Angola, Central African
Republic, Republic of Congo and Democratic Republic of Congo, 1995–2006. a Among these 906 exclusions there are 125 patients that relapsed
before 6 months (hence falling out of the scope of this study); b Tolerance window up to 9 months.
doi:10.1371/journal.pntd.0001662.g001
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65–274) and the 362 who later relapsed (132 cells, IQR 53–270)
(Wilcoxon test p = 0.15), whereas at 6 months it was significantly
higher among patients who later relapsed (29.5 cells, IQR 11–78)
than in patients who cured (4 cells, IQR 2–9) (p,0.001). This
difference increased at 12 and 18 months, as expected (Figure 2).
The difference was observed in all treatment groups, except at 6
and 12 months post-treatment in patients receiving drug
combinations, emerging from 18 months onwards.
The evolution of the CSF leucocytes count was similar in naı¨ve
(first-time treated) and non-naı¨ve patients throughout the post-
therapeutic follow-up (data not shown).
Prediction of final outcome at 6 months
The ROC analysis showed that the absolute CSF leucocytes
count at 6 months was at least as good a predictor of outcome
(AUC 0.84) as the percent reduction (AUC 0.81). The latter being
also the least practical (requiring a bedside calculation involving
the initial laboratory results), we did not explore it further. The
CSF leucocytes count at 6 months showed the best trade off
between sensitivity and specificity at cut-off values of 10 to 13
leucocytes/mL. The best accuracy was obtained with a cut-off at
.10 leucocytes/mL which predicted relapse with 76.2% (95%CI,
71.84–80.65%) sensitivity, 80.4% (95%CI, 78.37–82.45%)
specificity, 3.89 (95%CI, 3.45–4.38) LR+, 0.29 (95%CI, 0.26–
0.32) LR2 (Table 2). The positive predictive value was 0.49
(95%CI, 0.45–0.53) and the negative predictive value 0.93
(95%CI, 0.92–0.94).
The multivariate analysis confirmed, after adjustment on
treatment, age and sex, that the six-months CSF leucocytes count,
with a cut-off at 10 cells, was very strongly associated with the risk
of relapse (odds ratio = 17.2, 95%CI, 12.6–23.5).
Prediction of final outcome by algorithms at 6 and 12
months
Table 3 shows the performance of the two-steps algorithms
when tested with our large dataset (n = 2190) of selected patients
with laboratory-confirmed outcome. In the first line we show the
results reported by Mumba et al. [6] on a smaller cohort
(‘‘algorithm 5-50-20’’).
The same algorithm in our dataset predicted relapse with 87.4%
sensitivity (95%CI, 85–90), 97.7% specificity (95%CI, 97–98),
LR+ of 37.84 (95%CI, 26.4–54.3) and LR2 of 0.13 (95%CI,
0.11–0.16). It wrongly classified as cured (false negatives) 87/1945
patients (4.5%; 95%CI, 3.6–5.5). Two thirds (66.4%; 95%CI,
64.4–68.4%) of the patients followed-up were already classified at
6 months.
The algorithms 5-40-20 and 5-40-15 also performed well, with
confidence intervals overlapping the algorithm 5-50-20. The 5-30-
15 algorithm was slightly more sensitive but less specific. The
proportion of patients classified as cured who later relapsed ranged
Table 1. Baseline characteristics of patients included in each analysis.
Characteristics of the patients First analysis (N=1822) Second analysis (N=2190)
N N
Sex ratio (M/F) 1821 1.08 (947/874) 2189 1.12 (1159/1030)
Age, median [IQR] 1822 24 [15–35] 2190 24 [15–35]
Weight, median [IQR] 712 49 [9–56] 951 49 [40–56]
Detected by active screening, n (%) 1822 360 (19.8) 2190 405 (18.5)
Trypanosomes detected 1822 2190
In lymph nodes, n (%) 879 (48.2) 1073 (49.0)
In blood, n (%) 606 (33.2) 712 (32.5)
In CSF, n (%) 1328 (72.9) 1626 (74.3)
CSF leukocyte count 1822 2190
Mean (SD) 233.2 (326.8) 240.8 (321.5)
Median [IQR] 133 [56–272] 141 [62–287]
20–99 cells/mL n(%) 733 (40.2) 817 (37.3)
$100 cells/mL n(%) 1089 (59.8) 1373 (62.7)
Clinical characteristics
Coma score ,15, n (%) 626 29 (4.6) 798 34 (4.3)
Karnofsky index, median [IQR] 641 80 [70–80] 831 80 [70–80]
Treatment naivety 1822 1485 (81.5) 2190 1753 (80.0)
Treatment received 1822 2190
Melarsoprol n(%) 1151 (63.2) 1469 (67.1)
Eflornithine n(%) 540 (29.6) 578 (26.4)
Combinations n(%) 131 (7.2) 143 (6.5)
Patients that relapsed n(%) 1822 362 (19.9) 2190 730 (33.3)
First analysis: leukocytes at 6 months, excluding relapses at 6 months; Second analysis: leukocytes at 6 months, including relapses at 6 months, two-step algorithms.
Combination treatment: within this selected cohort, it included melarsoprol-eflornithine, nifurtimox-eflornithine and melarsoprol-nifurtimox combinations. Coma score:
Glasgow Coma Scale assessing the level of consciousness. Interpretation: 3–8 = severe impairment; 9–12 =moderate impairment; 13–14 =mild impairment; 15 = normal
[13]; Karnofsky index [14].
doi:10.1371/journal.pntd.0001662.t001
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from 3.5 to 4.5% in all tested algorithms. The portion of the
cohort classified at 6 months ranged from 66.4 to 74.1%, leaving
the rest to be classified at 12 months. Of the algorithms tested, the
5-50-20 appeared as the best overall with the highest LR+ and a
proportion of false negatives not significantly different from the
other algorithms (Figure 3).
Discussion
The CSF leucocytes count at 6 months showed a good
prognostic value for final efficacy outcome. However, a small
proportion of patients was wrongly classified. Translated into field
patient management, those wrongly classified as relapsed would be
Figure 2. Evolution of the CSF leucocytes count by final treatment outcome, by treatment group and overall. CSF leucocytes count
expressed as the median and interquartile range (IQR). Cohort of 1822 patients having a leukocytes count performed at 6 months and not relapsing
at 6 months or earlier, who had a complete follow-up. Values at month 0 are pre-treatment measurements. The number of patients per group is
shown at each time point. Dotted lines are used to signify that samples over time contain some different patients.
doi:10.1371/journal.pntd.0001662.g002
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unnecessarily re-treated, sometimes with toxic drugs (e.g. melar-
soprol if first-line treatment was eflornithine or eflornithine-
nifurtimox) and, more importantly, patients wrongly classified as
cured would be at risk of death due to HAT relapse. A two-step
algorithm, at 6 and 12 months, provided a better classification tool
featuring an excellent ability to predict relapses with a lower
misclassification rate.
At 6 months, the CSF leucocytes cut-off at 10/mL had the best
trade-off between positive and negative likelihood ratios. This
indicator can rule out relapse at 6 months post-treatment with a
good degree of confidence (0.93 negative predictive value), but its
ability to identify true relapses is sub-optimal.
Other cut-off values may be of interest for decision-making in
the context of clinical trials, e.g. to continue or suspend enrolment
of new participants based on 6-months data (patients already
enrolled would always benefit of complete follow up).
It is important to underline that the relapse rate was 19.9% in
our dataset (first analysis), which is much higher than the relapse
rate reported with the new and increasingly used nifurtimox-
eflornithine combination therapy (NECT) [10,11]. Because
positive and negative predictive values depend on the relapse
rate, the lower the relapse rate is, the lower will be the positive
predictive value for relapse, but on the other hand the negative
predictive value will be higher, increasing the confidence on the
prediction of cure. Reporting the likelihood ratios allows to make
abstraction of this phenomenon, since they are independent from
relapse rates. Likelihood ratios, both LR+ and LR2 are one of the
best ways to measure diagnostic accuracy. In medicine, a test is
generally regarded as valuable when the LR+ is .5 or the LR2 is
,0.2 [9,12].
Because the CSF leucocytes count at 6 months alone remains
insufficiently accurate for outcome determination, we evaluated
various two-step algorithms at 6 and 12 months, following the
model published by Mumba et al [6].
All tested algorithms performed well, but the 5-50-20 algorithm
showed the highest specificity (97.7%) and LR+ (37.8). The
sensitivity (87.4%), LR2 (0.13) and proportion of patients falsely
declared as cured (4.5%) were statistically comparable to the other
tested algorithms (table 3, figure 3). Two-third of patients (66.4%)
could be classified at 6-months post-treatment. Algorithms that
would increase this proportion (such as 5-20-20, 5-20-15 or 5-20-
10 that classify 74.1% of patients at 6-months) could be
particularly interesting in settings with poor follow-up compliance
beyond the first visit at 6 months.
Our findings therefore confirm that the diagnostic algorithm 5-
50-20 performs well to predict post-treatment outcome, allowing
for a shorter follow-up period.
Other algorithms can be applied depending on the setting and
priority objectives, e.g. clinical trials or individual patient
management in settings with poor follow-up compliance such as
in conflict areas.
In all cases, patients who are declared cured early by using these
predictors should be encouraged to come for control if symptoms
reappear later.
Early determination of outcome presents several key advantages
for HAT control programs: first, it cuts down on uncured patients
remaining infective until eventually detected or dying; second, it
reduces the workload and costs of follow-up; third, it facilitates the
monitoring of treatment effectiveness. For some patients it is life-
saving or preventive of serious sequelae, for most others it reduces
Table 2. Performance of different cut-off values of CSF leucocytes count at 6 months for the detection of relapse.
Cut-off of CSF leucocytes
count at 6 months Sensitivity Specificity Correctly classified Likelihood Ratio
Positive Negative
.5 83.98% 60.21% 64.93% 2.11 0.27
.10 76.24% 80.41% 79.58% 3.89 0.29
.20 59.67% 93.49% 86.77% 9.17 0.43
doi:10.1371/journal.pntd.0001662.t002
Table 3. Comparison of several two-steps (6 and 12 months) algorithms for early outcome determination.
Algorithm n Sensitivity (95%CI) Specificity (95%CI) LR+ (95%CI) LR2 (95%CI)
False
cured (95%CI)
% classified
at 6 months
5-50-20a 213 94.4 (86–98) 97.8 (94–100) 42.20 (13.8–129.3) 0.06 (0.02–0.15) 1.9 (0.5–4.9) 66.2
5-50-20b 2190 87.4 (85–90) 97.7 (97–98) 37.84 (26.4–54.3) 0.13 (0.11–0.16) 4.5 (3.6–5.5) 66.4
5-20-20 2190 89.4 (87–92) 92.0 (90–93) 11.12 (9.2–13.4) 0.12 (0.09–0.14) 3.8 (3.0–4.7) 74.1
5-20-15 2190 90.0 (88–92) 91.7 (90–93) 10.87 (9.0–13.1) 0.11 (0.09–0.14) 3.6 (2.8–4.5) 74.1
5-20-10 2190 90.1 (88–92) 90.8 (89–92) 9.78 (8.2–11.6) 0.11 (0.09–0.14) 3.5 (2.8–4.4) 74.1
5-30-15 2190 89.4 (87–92) 95.4 (94–97) 19.52 (15.2–25.1) 0.11 (0.09–0.14) 3.8 (3.0–4.7) 70.1
5-40-20 2190 87.7 (85–90) 97.1 (96–98) 29.90 (21.7–41.1) 0.13 (0.10–0.15) 4.4 (3.5–5.4) 67.8
5-40-15 2190 88.7 (86–91) 96.8 (96–98) 27.29 (20.2–36.9) 0.12 (0.10–0.14) 4.0 (3.2–5.0) 67.8
5-40-10 2190 89.5 (87–92) 95.2 (94–96) 18.80 (14.7–24.1) 0.11 (0.09–0.12) 3.7 (2.9–4.7) 67.8
aAs reported by Mumba 2010, ‘‘algorithm C’’: includes deaths as treatment failures and patients with incomplete follow-up;
bSame algorithm tested with our dataset including only laboratory-confirmed outcomes. LR: Likelihood ratio. False cured: fraction of patients that are wrongly classified
as cured by the algorithm.
doi:10.1371/journal.pntd.0001662.t003
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the burden of complying with follow-up schemes. For clinical
studies it accelerates acquisition of results and decreases costs.
Strengths and weaknesses
One major strength of this study was the restrictive selection
criteria, which minimized information bias that is typically present
in HAT studies: most cohorts include important proportions of
patients with uncertain or unknown efficacy outcome, due to the
difficulties in completing the patients’ follow-up.
Another strength was the large sample size, which increases the
precision of the findings.
Finally, the statistical methods used, in particular the analysis by
logistic regression with a random intercept controlling the inter-
site heterogeneity.
A weakness arose from the nature of the data used, collected by
field routine programs, which is generally of lower quality than
data collected prospectively within planned studies.
Another weakness arises from the reference used for ‘‘true
outcome’’: a composite definition based on the presence of
Figure 3. Relationship between the positive likelihood ratio (LR+) and the proportion of patients wrongly classified as cured, for
each algorithm tested.
doi:10.1371/journal.pntd.0001662.g003
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trypanosomes or a CSF leucocytes count $50. The predictors
studied are also based on the CSF leucocytes count (at an earlier
time) and are therefore not independent from the outcome
measurement. In particular when the predictor includes the same
value (CSF leucocytes count $50, such as in the algorithm 5-50-
20) the specificity is to some extent over-estimated.
The marker at the center of our analysis, the CSF leucocytes
count, is subject to measurement error, being a manual laboratory
technique. However, this particular laboratory exam is regarded as
crucial for the patient and it has been the object of great attention
in the MSF sites that were included in this study. Internal quality
control was implemented in all field laboratories, through blinded
double and triple CSF leucocytes counts, showing good levels of
consistency in the results (authors’ direct field observation, data
not published). To our knowledge there are no published works to
shed more light into this issue.
The timing of the follow-up assessments was treated via the
consolidation of the visit dates into time ‘‘tolerance’’ windows,
which are arbitrary groupings (we followed conventional windows)
[2]. This interval censoring is an imperfect way of capturing the
timing of events: for example what we treat as the ‘‘6 months’’
leucocytes count in reality happened anywhere between 5 and 9
months, with an uneven spread that tends to concentrate after the
6-months date. This field data distribution can be assumed to
correspond well with the reality of the routine programs, but it will
fit less the temporal distribution in clinical trials that usually have
intensive follow-up of patients.
Conclusions
This study provides robust evidence on the value of the CSF
leucocytes count to predict, at 6 and 12 months, the efficacy
outcome of second-stage T. b. gambiense HAT treatment.
For decision-making on individual patients followed-up in the
field, our findings confirm the good performance of the two-steps
algorithm using cut-off values of 5-50-20 leucocytes/mL. Other
algorithms can be used depending on the setting.
For the early estimation of efficacy in clinical trials, several
options are revealed, both in one step at 6 months and in two steps
at 6 and 12 months.
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